CDT (Conduit Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals 5-Year Dividend Growth Rate?

Conduit Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Conduit Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Conduit Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Conduit Pharmaceuticals's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Conduit Pharmaceuticals's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conduit Pharmaceuticals's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's 5-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

Conduit Pharmaceuticals 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Conduit Pharmaceuticals (NAS:CDT) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Conduit Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-6.616
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conduit Pharmaceuticals 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Executives

Andrew Regan	director, 10 percent owner	LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Intelmed Llc	other: See Responses	11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay	director, officer: Chief Executive Officer	32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc.	10 percent owner, other: See Responses	100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd.	10 percent owner, other: See Responses	WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh	director	38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc	10 percent owner	230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg	director	2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc	10 percent owner	4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley	director	4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv	officer: Chief Accounting Officer	2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron	director, officer: CEO, President, and Chairman	16433 BRONCO LANE, POWAY CA 92064